bone marrow-derived mesenchymal stem cells / Be The Match BioTherapies, ImmunityBio - LARVOL DELTA

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: ImmunityBio, Inc. | Phase classification: P1b ➔ P1 | N=45 ➔ 4 | Active, not recruiting ➔ Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

Enrollment change • Immunomodulating • Phase classification • Trial termination • Infectious Disease • Novel Coronavirus Disease • CRP

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation (clinicaltrials.gov) - P1b | N=45 | Active, not recruiting | Sponsor: ImmunityBio, Inc. | Trial completion date: Jun 2021 ➔ Jun 2022 | Trial primary completion date: Jun 2021 ➔ Jun 2022

Trial completion date • Trial primary completion date • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • CRP • PCR

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation (clinicaltrials.gov) - P1b; N=45; Active, not recruiting; Sponsor: ImmunityBio, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • CRP • PCR

ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company (NantKwest) - "Broad late-stage pipeline for solid tumors including bladder, lung, breast, and pancreatic in addition to infectious disease programs for HIV and COVID-19; ImmunityBio...today announced they have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a leading immunotherapy and cell therapy company focused on oncology and infectious disease."

M&A • Infectious Disease • Novel Coronavirus Disease

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation (clinicaltrials.gov) - P1b; N=45; Recruiting; Sponsor: NantKwest, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • PCR

NantKwest announces FDA authorization of IND application for mesenchymal stem cell product for the treatment of severe Covid-19 patients (Businesswire) - "NantKwest, Inc....today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC....NantKwest has entered into an agreement with the National Marrow Donor Program....The Phase 1b, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BM-Allo.MSC versus current supporting care in treating patients with severe disease and requiring ventilator support (IND 019735). The therapeutic will be administered to a total of 45 patients receiving care in the critical care or ICU setting."

IND • Licensing / partnership • New P1 trial • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease

Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation (clinicaltrials.gov) - P1b; N=45; Not yet recruiting; Sponsor: NantKwest, Inc.

Clinical • New P1 trial • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease